Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

ABSTRACT:

Background

HIV-infected individuals, even well controlled with combined antiretroviral therapy (cART), have systemic inflammation and comorbidities. Substance P (SP) is an undecapeptide, which mediates neurotransmission and inflammation through its cognate neurokinin 1 receptor (NK1R). Plasma SP levels are elevated in HIV-infected individuals. The FDA-approved antiemetic aprepitant, an NK1R antagonist, has anti-HIV effects and antiinflammatory actions. We evaluated the safety, pharmacokinetics, and antiinflammatory properties of aprepitant in HIV-positive individuals receiving cART.

Methods

We conducted a phase 1B study of 12 HIV-positive individuals on a ritonavir-containing regimen (HIV viral load less than 40 copies/ml and CD4 > 400 cells/μl). Participants received open-l

SUBMITTER: Spitsin S 

PROVIDER: S-EPMC5841871 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature